Molecular and Clinical Profile of Von Willebrand Disease in Spain

Plain-language summary

This study examines the molecular and clinical features of Von Willebrand disease in Spain through analysis of the VWF gene. It enrolled patients with low VWF levels or a mutation in the VWF gene. It was conducted as a study without a phase and has been completed.

The summary above is a plain-language rendering of the official record. The original English title is shown for reference.

Trial details

Phase

N/A

Status

Completed

Sponsor

Spanish Society of Thrombosis and Haemostasis

Intervention

VWF gene analysis

Start date

10/3/2017

Estimated completion

9/25/2021

Countries

Spain

Related genes

Locations

• Oviedo, Spain

Eligibility criteria

Criteria are reproduced from the ClinicalTrials.gov record in the original English. Only the trial team can determine eligibility.

Inclusion Criteria: One or more of the following:

1. VWF ≤ 30 IU/d, in 2 or more occasions.
2. Presence of multimeric abnormalities.
3. If isolated FVIII deficiency demonstration of decreased FVIII binding.
4. Presence of some VWF mutation.
5. ↑ RIPA at low concentrations of ristocetin.

Exclusion Criteria:

1. Presence of any data suggesting AVWS.
2. Absence of a signed patient informed consent